Fulgent Genetics Inc
NASDAQ:FLGT
Balance Sheet
Balance Sheet Decomposition
Fulgent Genetics Inc
Current Assets | 507.8m |
Cash & Short-Term Investments | 424.2m |
Receivables | 57.4m |
Other Current Assets | 26.2m |
Non-Current Assets | 727.5m |
Long-Term Investments | 423.6m |
PP&E | 95.6m |
Intangibles | 165.1m |
Other Non-Current Assets | 43.2m |
Current Liabilities | 73m |
Accounts Payable | 15.4m |
Accrued Liabilities | 30.7m |
Other Current Liabilities | 26.9m |
Non-Current Liabilities | 26.2m |
Long-Term Debt | 3.8m |
Other Non-Current Liabilities | 22.4m |
Balance Sheet
Fulgent Genetics Inc
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
0
|
1
|
8
|
7
|
7
|
12
|
87
|
165
|
80
|
97
|
|
Cash Equivalents |
0
|
1
|
8
|
7
|
7
|
12
|
87
|
165
|
80
|
97
|
|
Short-Term Investments |
0
|
0
|
13
|
20
|
24
|
16
|
212
|
286
|
447
|
327
|
|
Total Receivables |
0
|
2
|
5
|
6
|
8
|
7
|
204
|
145
|
91
|
57
|
|
Accounts Receivables |
0
|
2
|
5
|
4
|
6
|
7
|
185
|
139
|
53
|
51
|
|
Other Receivables |
0
|
0
|
0
|
2
|
2
|
1
|
19
|
6
|
38
|
6
|
|
Other Current Assets |
0
|
0
|
1
|
1
|
1
|
2
|
20
|
16
|
11
|
26
|
|
Total Current Assets |
1
|
3
|
26
|
33
|
40
|
37
|
524
|
612
|
628
|
508
|
|
PP&E Net |
1
|
3
|
6
|
7
|
6
|
9
|
41
|
71
|
99
|
96
|
|
PP&E Gross |
1
|
3
|
6
|
7
|
6
|
9
|
41
|
71
|
99
|
96
|
|
Accumulated Depreciation |
0
|
1
|
2
|
4
|
6
|
8
|
11
|
20
|
43
|
52
|
|
Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
36
|
151
|
143
|
|
Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
51
|
143
|
22
|
|
Long-Term Investments |
0
|
0
|
26
|
17
|
8
|
43
|
133
|
485
|
327
|
424
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
24
|
39
|
43
|
|
Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
51
|
143
|
22
|
|
Total Assets |
2
N/A
|
6
+176%
|
58
+900%
|
57
-1%
|
54
-6%
|
89
+65%
|
701
+689%
|
1 279
+83%
|
1 386
+8%
|
1 235
-11%
|
|
Liabilities | |||||||||||
Accounts Payable |
0
|
0
|
3
|
2
|
1
|
2
|
27
|
21
|
23
|
15
|
|
Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
9
|
18
|
25
|
31
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
15
|
21
|
21
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
80
|
46
|
19
|
25
|
|
Total Current Liabilities |
0
|
1
|
3
|
3
|
3
|
4
|
130
|
105
|
88
|
73
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
|
Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
10
|
14
|
|
Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
3
|
3
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
1
|
5
|
16
|
11
|
|
Total Liabilities |
0
N/A
|
1
+75%
|
4
+414%
|
3
-17%
|
3
-7%
|
6
+114%
|
131
+2 085%
|
120
-8%
|
119
-1%
|
99
-17%
|
|
Equity | |||||||||||
Common Stock |
12
|
58
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
10
|
53
|
55
|
58
|
63
|
63
|
151
|
658
|
801
|
633
|
|
Additional Paid In Capital |
0
|
0
|
110
|
112
|
114
|
146
|
418
|
502
|
487
|
502
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
21
|
1
|
|
Total Equity |
2
N/A
|
5
+200%
|
55
+969%
|
54
-1%
|
51
-6%
|
83
+62%
|
569
+588%
|
1 159
+103%
|
1 267
+9%
|
1 136
-10%
|
|
Total Liabilities & Equity |
2
N/A
|
6
+176%
|
58
+900%
|
57
-1%
|
54
-6%
|
89
+65%
|
701
+689%
|
1 279
+83%
|
1 386
+8%
|
1 235
-11%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
17
|
17
|
18
|
18
|
18
|
22
|
28
|
30
|
29
|
30
|